4-(5-甲基-1H-苯并咪唑-2-基)苯胺 | 110178-74-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 4-(5-甲基-1H-苯并咪唑-2-基)苯胺
• 中文别名: 4-(5-甲基-1H-苯并咪唑基-2-基)-苯基胺；[4-(6-甲基-1H-苯并咪唑-2-基)苯基]胺；4-(6-甲基-1H-苯并咪唑-2-基)苯胺
• 英文名称: 4-(5-methyl-1H-benzimidazol-2yl)aniline
• 英文别名: JTR-009；4-(5-methyl-1(3)H-benzimidazol-2-yl)-aniline；4-(5-Methyl-1(3)H-benzimidazol-2-yl)-anilin；4-(6-methyl-1H-benzimidazol-2-yl)aniline
• CAS: 110178-74-0
• 化学式: C₁₄H₁₃N₃
• mdl: MFCD00628968
• 分子量: 223.277
• InChiKey: BQAHOIQJVNOZKN-UHFFFAOYSA-N

物化性质

• 沸点：
  474.8±47.0 °C(Predicted)
• 密度：
  1.247±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  4-(5-甲基-1H-苯并咪唑-2-基)苯胺 、 2-hydroxy-4-(octyloxy)benzaldehyde 在 溶剂黄146 作用下， 反应 4.0h， 以68%的产率得到(4′-(5″-methyl-1H-benzimidazole)-phenyl)-4-octyloxysalicylaldimine
  参考文献：
  名称：

  Benzimidazole based mesogenic Schiff-bases: Synthesis and characterization

  摘要：

  Two homologous series of mesogenic Schiff-bases, N-4-((alkoxy)-(phenyl-3-hydroxy-4-(4-(5-methylbenzimidazol))-2-alkoxysalicylaldimine)benzoate (7a-d) and N-4'-(5-methyl-benzimidazole)-phenyl-4-alkoxysalicylaldimine (8a-d) incorporating benzimidazole moiety have been prepared and the molecular structures studied by FT-IR, NMR and ESI-MS spectrometry. Mesogenic behaviour was investigated by polarizing optical microscopy (POM), differential scanning calorimetry (DSC) and variable temperature powder X-ray diffraction (PXRD) techniques. Changing the spacer (ester-linked to non-ester linked) of the Schiff-base results in enhancement of thermal stability and phase transition temperature. The members of series-I show monotropic SmA while those of series-II reflect enantiotropic SmA mesomorphism. An electrochemical study of a representative Schiff base in each series (7d and 8c) showed an electrical band gap 1.26 eV and 122 eV respectively. (C) 2017 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.molliq.2017.05.061
• 作为产物：
  描述：

  N-(4-甲基苯基)-4-硝基苯甲酰胺 在 盐酸 、 乙醇 、 硝酸 、 tin(ll) chloride 作用下， 生成 4-(5-甲基-1H-苯并咪唑-2-基)苯胺
  参考文献：
  名称：

  Lellmann; Hailer, Chemische Berichte, 1893, vol. 26, p. 2762

  摘要：

  DOI：

文献信息

• Efficient Synthesis of Benzimidazoles Containing 1,2,4-Triazol-3-One Nucleus Using Microwave Technique
  作者：Emre Menteşe、Bahittin Kahveci

  DOI：10.1007/s10593-017-1991-2

  日期：2016.11

  A series of new compounds containing both benzimidazole and 1,2,4-triazol-3-one rings was synthesized by microwave irradiation of mixtures containing 5-(alkyl/phenyl)-4-(4-carboxyphenyl)-2,4-dihydro-3H-1,2,4-triazol-3-ones and 1,2-diaminobenzene derivatives. Also, benzimidazole derivatives were synthesized by the reaction of ethyl 2-(ethoxy(alkyl/phenyl)methylene)hydrazine-1-carboxylates with 2-aminobenzimidazole

  通过微波辐射含有5-（烷基/苯基）-4-（4-羧苯基）-2,4-二氢的混合物，合成了一系列同时含有苯并咪唑和1,2,4-三唑-3-环的新化合物-3 H -1,2,4-三唑-3-酮和1,2-二氨基苯衍生物。同样，通过2-（乙氧基（烷基/苯基）亚甲基）肼-1-羧酸乙酯与2-氨基苯并咪唑的反应合成苯并咪唑衍生物。这项研究首次实现了1,2,4-三唑-3-酮和苯并咪唑环体系的快速有效结合。
• Piperidinyl and piperazinyl compounds substituted with bicyclo-heterocyclylalkyl groups useful as CCR3 receptor antagonists
  申请人：Gong Leyi

  公开号：US20050090504A1

  公开（公告）日：2005-04-28

  Compounds having the Formula (I), are useful as CCR3 receptor antagonists, wherein Ar is aryl or heteroaryl; Q is —C(═O)— or C 1-2 alkylene; X is N( + )R 9a , or N; Y is CR 9b , or N; R 2 is hydrogen or alkyl; R 3 and R 4 are as defined in the specification; U c is a mono- or bicyclic group as defined in the specification; n is 0 or 1; and p is 0, 1, 2, 3 or 4.

  具有化学式（I）的化合物，作为CCR3受体拮抗剂是有用的，其中Ar是芳基或杂环芳基；Q是—C(═O)—或C1-2烷基；X是N(+)R9a，或N；Y是CR9b，或N；R2是氢或烷基；R3和R4如规范中所定义；Uc是如规范中定义的单环或双环基团；n为0或1；p为0, 1, 2, 3或4。
• Benzimidazole compounds for regulating IgE
  申请人：——

  公开号：US20030100582A1

  公开（公告）日：2003-05-29

  This invention relates to a family of phenylbenzimidazole analogs, which are inhibitors of the IgE response to allergens. These compounds are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.

  这项发明涉及一类苯基苯并咪唑类似物，它们是抑制对过敏原的IgE反应的抑制剂。这些化合物在治疗过敏和/或哮喘或任何IgE致病的疾病中是有用的。
• Benzimidazole derivatives as modulators of IgE
  申请人：Avanir Pharmaceuticals

  公开号：US06303645B1

  公开（公告）日：2001-10-16

  This invention relates to a family of diacyl benzimidazole analogs, which are inhibitors of the IgE response to allergens. These compounds are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.

  本发明涉及一类二酰基苯并咪唑类似物，它们是抑制IgE对过敏原反应的抑制剂。这些化合物在过敏和/或哮喘或任何IgE是致病因素的疾病的治疗中是有用的。
• TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
  申请人：Wynne Graham Michael

  公开号：US20090075938A1

  公开（公告）日：2009-03-19

  There are disclosed compound of Formula (1): A 1 , A 2 , A 3 and A 4 which may be the same or different, represent N or CR 1 , X is a divalent group selected from O, S(O) n , C═W, NR 4 , NC(═O)R 5 and CR 6 R 7 , W is O, S, NR 20 , Y is N or CR 8 , one of R 4 , R 5 , R 6 , R 8 , R 9 and NR 20 represents -L-R 3 , in which L is a single bond or a linker group, additionally, R 1 , R 3 -R 9 , which may be the same or different, independently represent hydrogen or a substituent and R 20 represents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO 2 , NR 30 R 31 , in which R 30 and R 31 , which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of R 30 and R 31 may represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent pair of A 1 -A 4 each represent CR 1 , then the adjacent carbon atoms, together with their substituents may form a ring B, when X is CR 6 R 7 , R 6 and R 7 , together with the carbon atom to which they are attached may form a ring C, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.

  公式（1）的化合物被揭示：A1，A2，A3和A4，它们可以相同或不同，代表N或CR1，X是从O，S（O）n，C═W，NR4，NC（═O）R5和CR6R7中选择的二价基团，W是O，S，NR20，Y是N或CR8，R4，R5，R6，R8，R9和NR20中的一个表示-L-R3，在其中L是单键或连接基团，此外，R1，R3-R9可以相同或不同，独立地表示氢或取代基，R20表示氢，羟基，可以用芳基取代的烷基，可以用芳基取代的烷氧基，芳基，CN，可以用芳基取代的烷氧基，可以用芳基取代的芳氧基，可以用取代基取代的烷酰基，可以用取代基取代的芳酰基，NO2，NR30R31，在其中R30和R31可以相同或不同，表示氢，可选地取代的烷基或可选地取代的芳基；此外，R30和R31中的一个可以表示可选地取代的烷酰基或可选地取代的芳酰基，n表示从0到2的整数，另外，当相邻的A1-A4中的一对表示CR1时，那么相邻的碳原子及其取代基可以形成环B，当X为CR6R7时，R6和R7与它们附着的碳原子一起可以形成环C，或其药学上可接受的盐，在制造用于治疗和/或预防杜氏肌萎缩症，贝克肌萎缩症或消瘦症的药物时使用。